{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:54:28Z","timestamp":1793850868592,"version":"4.6.1"},"reference-count":54,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.neuropharm.2013.07.027","type":"journal-article","created":{"date-parts":[[2013,8,15]],"date-time":"2013-08-15T12:45:22Z","timestamp":1376570722000},"page":"365-379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["The phenothiazine-class antipsychotic drugs prochlorperazine and trifluoperazine are potent allosteric modulators of the human P2X7 receptor"],"prefix":"10.1016","volume":"75","author":[{"given":"Christoph","family":"Hempel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"N\u00f6renberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga","family":"Sobottka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Nicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2013.07.027_bib1","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1124\/mol.105.020164","article-title":"Potentiation of native and recombinant P2X7-mediated calcium signaling by arachidonic acid in cultured cortical astrocytes and human embryonic kidney 293 cells","volume":"69","author":"Alloisio","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.bbr.2008.10.018","article-title":"Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders","volume":"198","author":"Basso","year":"2009","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/B978-0-12-385526-8.00011-4","article-title":"P2X receptors in health and disease","volume":"61","author":"Burnstock","year":"2011","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib4","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1038\/cddis.2009.11","article-title":"Long-term (trophic) purinergic signalling: purinoceptors control cell proliferation, differentiation and death","volume":"1","author":"Burnstock","year":"2010","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib5","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/sj.bjp.0701278","article-title":"Properties of the pore-forming P2X7 purinoceptor in mouse NTW8 microglial cells","volume":"121","author":"Chessell","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0014-5793(98)01332-5","article-title":"Cloning and functional characterisation of the mouse P2X7 receptor","volume":"439","author":"Chessell","year":"1998","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib7","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1124\/pr.110.003129","article-title":"Activation and regulation of purinergic P2X receptor channels","volume":"63","author":"Coddou","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib8","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/sj.bjp.0702164","article-title":"Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors","volume":"125","author":"Colquhoun","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib9","first-page":"105","article-title":"Isolation and culture of human macrophages","volume":"290","author":"Davies","year":"2005","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib10","doi-asserted-by":"crossref","first-page":"7143","DOI":"10.1523\/JNEUROSCI.21-18-07143.2001","article-title":"Neuronal P2X7 receptors are targeted to presynaptic terminals in the central and peripheral nervous systems","volume":"21","author":"Deuchars","year":"2001","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib11","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/glia.20958","article-title":"P2X7 receptors mediate ischemic damage to oligodendrocytes","volume":"58","author":"Domercq","year":"2010","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2013.07.027_bib13","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.4049\/jimmunol.159.3.1451","article-title":"Extracellular ATP triggers IL-1\u03b2 release by activating the purinergic P2Z receptor of human macrophages","volume":"159","author":"Ferrari","year":"1997","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib14","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.4049\/jimmunol.173.7.4652","article-title":"The antibiotic polymyxin B modulates P2X7 receptor function","volume":"173","author":"Ferrari","year":"2004","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s11302-012-9300-0","article-title":"Pathophysiology of astroglial purinergic signalling","volume":"8","author":"Franke","year":"2012","journal-title":"Purinergic. Signal."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib16","first-page":"35","article-title":"Recent patents on novel P2X7 receptor antagonists and their potential for reducing central nervous system inflammation. Recent Pat CNS","volume":"5","author":"Friedle","year":"2010","journal-title":"Drug Discov."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1146\/annurev.ne.16.030193.001503","article-title":"Recent advances in the molecular biology of dopamine receptors","volume":"16","author":"Gingrich","year":"1993","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.schres.2008.05.026","article-title":"Variation in the purinergic P2RX7 receptor gene and schizophrenia","volume":"104","author":"Hansen","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bbr.2011.09.015","article-title":"Spinal P2X7 receptor mediates microglia activation-induced neuropathic pain in the sciatic nerve injury rat model","volume":"226","author":"He","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1365-2125.1991.tb03973.x","article-title":"Clinical pharmacology of prochlorperazine in healthy young males","volume":"32","author":"Isah","year":"1991","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib21","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1471-4159.2011.07590.x","article-title":"Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects","volume":"120","author":"Jafari","year":"2012","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.neuropharm.2008.06.067","article-title":"ATP-gated P2X cation-channels","volume":"56","author":"Jarvis","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.07.027_bib23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.tibs.2012.10.006","article-title":"Moving through the gate in ATP-activated P2X receptors","volume":"38","author":"Jiang","year":"2013","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neuron.2012.09.024","article-title":"Neuromodulation by extracellular ATP and P2X receptors in the CNS","volume":"76","author":"Khakh","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2013.07.027_bib26","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3109\/03639045.2011.617753","article-title":"Microneedle assisted iontophoretic transdermal delivery of prochlorperazine edisylate","volume":"38","author":"Kolli","year":"2012","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib27","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1016\/j.bbamem.2011.08.017","article-title":"The effect of anions on the human P2X7 receptor","volume":"1808","author":"Kubick","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2013.07.027_bib28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0028-3908(80)90134-3","article-title":"Inhibition by trifluoperazine of calmodulin-induced activation of ATPase activity of rat erythrocyte","volume":"19","author":"Levin","year":"1980","journal-title":"Neuropharmacology"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2013.07.027_bib29","doi-asserted-by":"crossref","first-page":"S232","DOI":"10.1038\/sj.bjp.0706400","article-title":"The role of inflammation in CNS injury and disease","volume":"147","author":"Lucas","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib30","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/bjp.2008.306","article-title":"Identification of regions of the P2X7 receptor that contribute to human and rat species differences in antagonist effects","volume":"155","author":"Michel","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1744-8069-5-20","article-title":"Antidepressants inhibit P2X4 receptor function: a possible involvement in neuropathic pain relief","volume":"5","author":"Nagata","year":"2009","journal-title":"Mol. Pain"},{"key":"10.1016\/j.neuropharm.2013.07.027_bib32","doi-asserted-by":"crossref","first-page":"11067","DOI":"10.1074\/jbc.M110.198879","article-title":"Clemastine potentiates the human P2X7 receptor by sensitizing it to lower ATP concentrations","volume":"286","author":"N\u00f6renberg","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1476-5381.2012.01987.x","article-title":"Positive allosteric modulation by ivermectin of human but not murine P2X7 receptors","volume":"167","author":"N\u00f6renberg","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib34","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/cercor\/bhq154","article-title":"Rodent cortical astroglia express in situ functional P2X7 receptors sensing pathologically high ATP concentrations","volume":"21","author":"Oliveira","year":"2011","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.neuropharm.2013.07.027_bib35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12154-009-0034-6","article-title":"An intercalation mechanism as a mode of action exerted by psychotropic drugs: results of altered phospholipid substrate availabilities in membranes?","volume":"3","author":"Oruch","year":"2010","journal-title":"J.\u00a0Chem. Biol."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib36","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00424-006-0061-x","article-title":"Vesicular release of ATP at central synapses","volume":"452","author":"Pankratov","year":"2006","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s002800000142","article-title":"A\u00a0phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A","volume":"46","author":"Raschko","year":"2000","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib38","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jpsychires.2009.10.005","article-title":"Single nucleotide polymorphisms that were identified in affective mood disorders affect ATP-activated P2X7 receptor functions","volume":"44","author":"Roger","year":"2010","journal-title":"J.\u00a0Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib39","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1523\/JNEUROSCI.0696-08.2008","article-title":"Facilitation of P2X7 receptor currents and membrane blebbing via constitutive and dynamic calmodulin binding","volume":"28","author":"Roger","year":"2008","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib40","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2174\/1568026043387160","article-title":"Dissecting individual current components of co-expressed human P2X1 and P2X7 receptors","volume":"4","author":"Seyffert","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1146\/annurev.pharmtox.39.1.313","article-title":"New insights into dopaminergic receptor function using antisense and genetically altered animals","volume":"39","author":"Sibley","year":"1999","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib42","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.neuron.2007.03.020","article-title":"Ivermectin interaction with transmembrane helices reveals widespread rearrangements during opening of P2X receptor channels","volume":"54","author":"Silberberg","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2013.07.027_bib43","article-title":"P2X7 receptors in neurological and cardiovascular disorders","volume":"2009","author":"Skaper","year":"2009","journal-title":"Cardiovasc. Psychiatry Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib44","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1096\/fj.09-138883","article-title":"The P2X7 purinergic receptor: from physiology to neurological disorders","volume":"24","author":"Skaper","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib45","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/545263","article-title":"P2X7 receptors as a transducer in the co-occurrence of neurological\/psychiatric and cardiovascular disorders: a hypothesis","volume":"2009","author":"Skaper","year":"2009","journal-title":"Cardiovasc. Psychiatry Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib46","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1126\/science.184.4143.1243","article-title":"Drugs, neurotransmitters, and schizophrenia","volume":"184","author":"Snyder","year":"1974","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2013.07.027_bib47","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/mp.2009.52","article-title":"Activation of brain interleukin-1\u03b2 in schizophrenia","volume":"14","author":"S\u00f6derlund","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.07.027_bib48","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.biopsych.2008.10.018","article-title":"The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia","volume":"65","author":"Song","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.07.027_bib49","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1046\/j.1471-4159.2002.00920.x","article-title":"Involvement of P2X7 receptors in the regulation of neurotransmitter release in the rat hippocampus","volume":"81","author":"Sperl\u00e1gh","year":"2002","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib50","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/BF00685561","article-title":"Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker","volume":"34","author":"Sridhar","year":"1994","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib51","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1085\/jgp.200910336","article-title":"P2X4 receptors in activated C8-B4 cells of cerebellar microglial origin","volume":"135","author":"Toulm\u00e9","year":"2010","journal-title":"J.\u00a0Gen. Physiol."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib52","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.neuint.2004.08.004","article-title":"Molecular and functional characterisation of glutamate transporters in rat cortical astrocytes exposed to a defined combination of growth factors during in\u00a0vitro differentiation","volume":"46","author":"Vermeiren","year":"2005","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib53","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0028-3908(97)00141-X","article-title":"Effects of divalent cations, protons and calmidazolium at the rat P2X7 receptor","volume":"36","author":"Virginio","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.07.027_bib54","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2174\/187152712803581137","article-title":"P2X7 receptors: channels, pores and more","volume":"11","author":"Volont\u00e9","year":"2012","journal-title":"CNS. Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.neuropharm.2013.07.027_bib55","doi-asserted-by":"crossref","first-page":"14213","DOI":"10.1523\/JNEUROSCI.2390-10.2010","article-title":"Experimental characterization and mathematical modeling of P2X7 receptor channel gating","volume":"30","author":"Yan","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.027_bib56","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/35096578","article-title":"Voltage-induced membrane movement","volume":"413","author":"Zhang","year":"2001","journal-title":"Nature"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813003444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813003444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T14:52:08Z","timestamp":1715871128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390813003444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":54,"alternative-id":["S0028390813003444"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.07.027","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The phenothiazine-class antipsychotic drugs prochlorperazine and trifluoperazine are potent allosteric modulators of the human P2X7 receptor","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.07.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}